The occurrence of ventricular arrhythmias attributed to streptokinase treatment in acute myocardial infarction' is not well defined. Holter monitoring was performed for 24 hours in 81 patients with suspected acute myocardial infarction randomised in a ratio of 2:1 to intravenous streptokinase 1P5 x 10' IU (n = 55) or placebo infusion (n = 26) 6-7 hours (mean) after the onset of symptoms. No episodes of ventricular fibrillation were recorded. For the whole 24 hour period and during the first three hours after the start of treatment the incidence and frequency of ventricular arrhythmias were similar in the patients randomised to streptokinase and to placebo. But when the results in patients randomised "early" after the onset of symptoms of suspected acute myocardial infarction were analysed separately the frequency of abnormal complexes, pairs, runs, and repetitive arrhythmias seemed to be higher in patients allocated to streptokinase. This may reflect arrhythmias associated with reperfusion.
Streptokinase induced thrombolytic treatment of acute myocardial infarction can reopen occluded vessels,'3 improve ventricular function,45 and prolong survival.' It has, however, been suggested that reperfusion produced by thrombolytic treatment"' may be associated with an increase in the incidence of early ventricular arrhythmias. Conversely, because post-infarction ventricular arrhythmias are more common after larger infarcts,'2 thrombolytic treatment, which seems to reduce infarct size,4 might be expected to decrease the overall incidence of arrhythmias. There are few controlled studies of the occurrence of ventricular arrhythmias in patients treated with fibrinolytic agents and those treated conventionally.
In the present study, 24 hour Holter monitoring was part of a double blind, placebo controlled randomised trial of intravenous streptokinase in acute myocardial infarction (ISIS-2 pilot'3) to assess the effects of thrombolytic treatment on ventricular arrhythmias. Arrhythmias occurring in the first few hours after the start of treatment (which might be related to reperfusion) and those occurring later during the first 24 hours (which might be related to infarct size) were assessed separately. Because some studies indicate that reperfusion rates may be inversely related to the time from onset of chest pain to the start of treatment,2 the influence of this delay on the incidence of ventricular arrhythmias was also investigated. 
Results

OCCURRENCE OF ARRHYTHMIAS
No episodes of ventricular fibrillation were seen in this small study. Overall there were no significant differences between the streptokinase and the placebo groups in the percentage of patients with ventricular arrhythmias (table 2) . Similarly, there were no significant differences betwen the treatment groups in the percentage of patients with arrhythmias within three hours of the start of thrombolytic treatment and the percentage with arrhythmia during the remaining 21 hours. In eight patients, there was a sudden increase in ventricular arrhythmias soon after the start of the infusion. These episodes lasted less than 90 min and were followed by infrequent ventricular arrhythmias during the remaining monitored hours (fig 1) . This pattern was more common (but not significantly so) in the streptokinase group (seven patients (13%)) than in placebo group (one patient (4%)).
When patients treated early (that is within six hours) after the onset of symptoms were considered separately, there was no significant difference in the percentage with arrhythmias in the different treatment groups (table 2). 
Repetitive arrhythmias
Figure 2 Percentage ofpatients and mean number of abnormal complexes, runs, and repetitive arrhythmias seen during thefirst 12 hours and 13-24 hours from randomisation. SK, streptokinase.
HOURLY FREQUENCY OF ARRHYTHMIAS
Overall there were no significant differences between the streptokinase and the placebo groups in the average hourly frequency of ventricular arrhythmias (table 3) . The hourly frequency of arrhythmias recorded within three hours of the onset of treatment and during the remaining 21 hours of recording was similar in the treatment and placebo groups. But for patients treated within six hours of the onset of pain there were significant differences between the treatment groups in the frequency of abnormal complexes, of pairs, of runs, and of repetitive arrhythmias (table 3) . This seemed to be largely the result of an increase in such arrhythmias during the first 12 hours after treatment (figs 2-4) and was not apparent among patients treated 6-24 hours after the onset of pain ( streptokinase given over about 2-5 hours), Cercek et al reported on the percentage of patients with arrhythmias attributed to reperfusion defined by non-invasive indices.'6 T,here was, however, no control group in this study with which to compare the patients given fibrinolytic treatment.
In the large GISSI trial conventional (that is non-Holter) electrocardiographic monitoring detected early arrhythmia in only 1-2% of the patients allocated to streptokinase treatment but in this trial the frequency of early arrhythmias was not recorded in the open-control patients.7 In a subgroup of 433 patients participating in GISSI, arrhythmic events were recorded by computerised coronary care or Holter monitoring during the first two hours after randomisation. No clear differences were demonstrated between the patients allocated to the streptokinase and control groups. '7 Ventricular fibrillation was not seen in any patient in the present Holter study, but this is not surprising given its small size. In the large ISIS-2 trial, the observed incidence of ventricular fibrillation during the first 24 hours after the start of treatment was similar in the patients allocated to streptokinase and placebo (2-8% v 2 8%, unpublished data), while ventricular fibrillation during hospital admission was somewhat less common in patients allocated to streptokinase (4 3% v 4-9%). A similar, non-significantly lower incidence of ventricular fibrillation in hospital was also seen in the GISSI and recent trials of other fibrinolytic agents. 8 
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The intention of the present Holter study was to assess the effects of streptokinase on arrhythmias in a randomised controlled study. Streptokinase did not seem to increase the overall percentage of patients with arrhythmia or the overall frequency of arrhythmias among the patients entered in the study, though there was a suggestion that streptokinase might be associated with an increased frequency of abnormal complexes, of runs, and of repetitive arrhythmias among patients treated early after the onset of pain. Because angiographic data were not available for patients in this study, this apparent excess of arrhythmias cannot be attributed definitely to myocardial reperfusion, though this seems to be a plausible hypothesis worthy of further study.
In this study intravenous streptokinase treatment seemed to have a low arrhythmogenic potential (and, indeed, larger studies suggest that serious arrhythmias may be less common with fibrinolytic treatment). Consequently, there may be little need for treatment with prophylactic antiarrhythmic agents in patients given fibrinolytic treatment, particularly in view of the lack of evidence for any benefits of these agents20 in the treatment of suspected acute myocardial infarction when fibrinolytic treatment is not used. 
